Core Viewpoint - The company reported a significant decline in revenue and a narrowed loss for the mid-year results of 2025, primarily due to a decrease in CDMO services [1] Financial Performance - Revenue for the period was 2.711 million, representing a year-on-year decrease of 40.6% [1] - The company incurred a loss of approximately 110 million, which is a 17.9% improvement compared to the previous year [1] - Earnings per share were reported at a loss of 0.27 [1] Operational Insights - The decrease in revenue is attributed mainly to a reduction in CDMO (Contract Development and Manufacturing Organization) services [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） (1) 截至2025年6月30日止六個月的中期業績公告；及 (2) 變更所得款項用途 創勝集團醫藥有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然公佈本公司 及其附屬公司（統稱「本集團」）截至2025年6月30日止六個月（「報告期間」）的未經 審核綜合業績，及與2024年同期經營業績的比較。該等業績乃基於報告期間的未 經審核綜合中期財務報表，而有關報表乃根據國際財務報告準則會計準則（「國際 財務報告準則」）而編製並已由本公司審計委員會（「審計委員會」）及本公司核數師 德勤•關黃陳方會計師行審閱。 於本公告內，「我們」及「我們的」指本公司（定義見上文）及倘文義另有所指，則 指本集團（定義見上文）。本公告所載若干金額及百分比數字已經約整，或約整至 小數點後一位 ...

Group 1 - The biotechnology sector in the Hong Kong stock market experienced a significant decline, with several companies reporting substantial drops in their stock prices [1] - Notable declines include Clover Biopharmaceuticals, which fell by 14.13%, and Beigene, which dropped by 8.33% [2] - Other companies such as Innovent Biologics and WuXi Biologics also saw declines exceeding 5%, indicating a broader trend of negative performance in the sector [1][2] Group 2 - The following companies reported specific percentage declines: Clover Biopharmaceuticals (-14.13%), Beigene (-8.33%), and Innovent Biologics (-6.50%) [2] - Additional companies with notable declines include Kintor Pharmaceutical (-6.38%), CanSino Biologics (-5.98%), and Zai Lab (-5.50%) [2] - The overall trend suggests a challenging environment for biotechnology stocks in the Hong Kong market [1]

相关事件 格隆汇8月15日丨创胜集团-B(06628.HK)宣布，谨定于星期三，2025年8月27日举行董事会会议，以考虑 及通过本集团截至2025年6月30日止的六个月中期业绩，及建议的中期股息(如有)，以及处理其他事 项。 创胜集团-B(06628.HK)拟8月27日举行董事会会议批准中期业绩 创胜集团-B(06628.HK)授出200万份购股 权 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容所產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 承董事會命 創勝集團醫藥有限公司 執行董事、主席兼首席執行官 錢雪明 香港，2025年8月15日 於本公告日期，本公司董事會成員包括執行董事、主席兼首席執行官錢雪明博 士，非執行董事徐莉博士以及獨立非執行董事唐稼松先生、張志華先生、Kumar Srinivasan博士及陳瑋女士。 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 董事會召開日期 創勝集團醫藥有限公司（「本公司」及其附屬公司，「本集團」）董事會（「董事會」） 茲通告謹定於星期三，2025年8月27日舉行董事會會議，以考慮及通過本集團截 至2025年6月30日止的六個月中期業績，及建議之中期股息（如有），以及處理其 他事項。 創勝集團醫藥有限公司 ...

财务数据显示，截至2024年12月31日，创胜集团-B实现营业总收入1126.1万元，同比减少79.09%；归母 净利润-2.9亿元，同比增长37.24%；毛利率35.55%，资产负债率37.38%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 资料显示，创胜集团医药有限公司是一家临床阶段的在生物药发现、研发、工艺开发和生产方面具有全 面综合能力的生物制药公司。2021年9月29日,创胜集团在香港联合交易所主板上市,股票代码:06628。创 胜集团总部位于苏州,已成功搭建了全球的业务布局:在苏州设有药物发现、临床和转化研究中心,创胜集 团总部及以连续灌流生产工艺为核心技术的生产基地也正在建设中;在杭州拥有工艺与产品开发中心以 及药物生产基地,在北京、上海、广州和美国普林斯顿分别设有临床开发中心,并在美国波士顿、洛杉矶 设立了对外合作中心。创胜集团的开发管线已有十三个治疗用抗体新药分子,涵盖肿瘤、骨科和肾病等 领域。 7月29日，截至港股收盘，恒生指数下跌0.15%，报25524.45点。创胜集团-B（06628.HK）收报3.5港元/ 股，上涨17.06%，成交量867.09万股，成交额3058.47 ...

Group 1 - The core viewpoint of the news highlights the significant stock performance of Chuangsheng Group-B, which has seen a year-to-date increase of 268.25%, outperforming the Hang Seng Index by 25.27% [1] - As of July 23, the stock price of Chuangsheng Group-B closed at HKD 2.88 per share, with a trading volume of 8.95 million shares and a turnover of HKD 24.56 million, reflecting a volatility of 31.03% [1] - Financial data indicates that for the year ending December 31, 2024, Chuangsheng Group-B reported total revenue of HKD 11.26 million, a year-on-year decrease of 79.09%, and a net profit attributable to shareholders of -HKD 290 million, an increase of 37.24% year-on-year [1] Group 2 - Chuangsheng Group is a clinical-stage biopharmaceutical company with comprehensive capabilities in drug discovery, development, process development, and production [2] - The company was listed on the Hong Kong Stock Exchange on September 29, 2021, and is headquartered in Suzhou, with a global business layout including research centers and production bases in various locations [2] - Chuangsheng Group has a pipeline of thirteen therapeutic antibody new drug molecules targeting areas such as oncology, orthopedics, and nephrology [2] Group 3 - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 2.5 times, with a median of 6.8 times, while Chuangsheng Group-B has a P/E ratio of -3.22 times, ranking 140th in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as Jingyou Pharmaceutical at 1.29 times, Kingsray Biotechnology at 1.61 times, and Dongrui Pharmaceutical at 3.28 times [1]

Core Viewpoint - The company announced promising preclinical results for its novel FGFR2b-targeted antibody-drug conjugate (ADC) TST105, which demonstrates enhanced anti-tumor activity compared to existing ADCs in models of gastric and colorectal cancers [1][2]. Group 1: Clinical Research Findings - TST105 utilizes a site-specific conjugation technology and a novel topoisomerase I inhibitor as its payload, showing significantly improved anti-tumor efficacy in preclinical gastric and colorectal cancer models compared to ADCs using MMAE as a payload [1]. - In vitro studies indicate that TST105 exhibits specific cytotoxic effects on gastric and colorectal cancer cells, with an efficacy range of 0.3 nM to 0.4 nM, and demonstrates a stronger bystander effect compared to MMAE-based ADCs [2]. - In vivo pharmacological studies reveal that TST105 achieves a tumor growth inhibition (TGI) rate of 91.25% at a dose of 3 mg/kg in gastric cancer models, compared to 48.32% for Bema-MMAE, with an overall response rate (ORR) of 70% for TST105 versus 0% for Bema-MMAE [2]. Group 2: Industry Context and Future Prospects - The company expressed excitement about the transformative potential of TST105 in treating FGFR2b-overexpressing tumors, emphasizing its commitment to advancing this promising candidate into clinical development [3]. - The AACR 2025 conference, scheduled for April 25-30, 2025, in Chicago, serves as a significant platform for sharing advancements in cancer research, bringing together scientists, clinicians, and advocates to discuss the latest breakthroughs in oncology [3].

Regulatory Approvals and Clinical Trials - The company has received regulatory approvals for its Claudin18.2 antibody osemitamab (TST001) from the US FDA, China's NMPA, and Korea's MFDS, entering a critical development phase for global Phase 3 trials[9] - The Phase II data presented at ASCO 2024 and ESMO 2024 showed promising efficacy of osemitamab (TST001) in combination with nivolumab and CAPOX for first-line treatment of advanced G/GEJ cancer patients[9] - The company achieved key regulatory approvals for its lead oncology asset, osemitamab (TST001), from the FDA, NMPA, and MFDS for the treatment of gastric cancer[19] - The global Phase III trial (TranStar301) for Osemitamab (TST001) has received approvals from the FDA, China's NMPA, and South Korea's MFDS for use in first-line treatment of Claudin18.2 expressing gastric cancer[47] - The company has received IND approval for the Phase II study of blosozumab (TST002) in China, aimed at verifying efficacy and tolerability[80] - The company has successfully held an FDA Type C meeting to agree on comparability strategies for the late-stage development and final registration filing of osemitamab (TST001)[94] Pipeline Development and Research - The company showcased compelling data from the Phase I trial of blosozumab (TST002) at the WCO-IOF-ESCEO conference, indicating significant improvements in bone density for osteoporosis patients[10] - The Chinese National Medical Products Administration has approved blosozumab (TST002) for Phase II clinical trials, indicating progress in the company's pipeline[10] - The company is advancing a novel antibody-drug conjugate (ADC) targeting LIV-1 for triple-negative breast cancer treatment, demonstrating good anti-tumor activity[10] - The company initiated preparatory studies for TST801, a dual-function antibody fusion protein targeting BAFF and TACI, with potential applications in autoimmune diseases[21] - The company has developed a diverse pipeline of 15 candidates targeting oncology, bone disorders, and kidney diseases, with all but one candidate developed internally[43] - TST003, a first-in-class humanized anti-GREMLIN-1 antibody, is currently undergoing global first-in-human trials[55] - TST012, an ADC candidate targeting FGFR2b, is in the preclinical stage and aims to complement the gastric cancer strategy with Osemitamab (TST001)[56] - TST105, a bispecific ADC candidate targeting FGFR2b and an undisclosed tumor antigen, is also in the preclinical stage, focusing on improving treatment windows for solid tumors[57] - The company is focusing on non-oncology projects addressing significant medical needs in bone and kidney diseases, with several candidates in development[62] Financial Performance - Revenue decreased from RMB 53.8 million for the year ended December 31, 2023, to RMB 11.3 million for the year ending December 31, 2024, primarily due to a reduction in CDMO services[17] - Other income decreased from RMB 37.3 million for the year ended December 31, 2023, to RMB 23.5 million for the year ending December 31, 2024, mainly due to a decrease in interest income and government grants[17] - R&D expenses decreased from RMB 382.0 million for the year ended December 31, 2023, to RMB 192.1 million for the year ending December 31, 2024, attributed to the advancement of key pipelines and resource reallocation[17] - Administrative and selling expenses decreased from RMB 117.4 million for the year ended December 31, 2023, to RMB 70.5 million for the year ending December 31, 2024, primarily due to reduced labor costs and professional services[17] - Adjusted loss and total comprehensive expenses decreased from RMB 437.3 million for the year ended December 31, 2023, to RMB 270.4 million for the year ending December 31, 2024, due to reallocation of R&D investments and reduced costs[17] - The company reported a net loss of RMB (290,292) thousand for the year ended December 31, 2024, compared to a net loss of RMB (462,570) thousand for the year ended December 31, 2023[114] Partnerships and Collaborations - The company aims to establish partnerships to maximize the potential of its pipeline molecules, focusing on core products[11] - The company is actively engaging potential partners to support the global development and commercialization of osemitamab (TST001), having received milestone payments from a research collaboration partner[36] - The company has established strategic collaborations with renowned academic institutions for translational research on multiple projects, enhancing its global leadership in Claudin18.2 targeted combination therapies[89] - The company is exploring global partnerships for supply of perfusion and feeding batch culture media[150] - The company is in discussions with several domestic pharmaceutical companies for collaboration on the development and commercialization of blosozumab (TST002) in the Greater China region[81] Intellectual Property and Patents - The company has secured patents for Claudin18.2 in China and Russia, with plans to obtain a Hong Kong patent in 2025[9] - The company successfully obtained a patent for Claudin18.2 from the National Intellectual Property Administration of China in August 2024 and from the Russian Federal Intellectual Property Office in November 2024[27] - The company has received a patent for Claudin18.2 in Hong Kong as of March 2025[102] Operational Efficiency and Cost Management - The company aims to enhance operational efficiency and reduce costs to improve competitiveness[111] - The company plans to develop a lyophilization technology to better serve customers[111] - The company has expanded its CDMO services, including the development of new generation perfusion media and lyophilization technology to support both internal and external projects[39] - The company has acquired lyophilization technology and optimized the development of lyophilization cycles to support both internal and external CDMO client plans[94] Market Strategy and Future Outlook - The company plans to continue expanding its product line and explore partnership opportunities to maximize the commercial value of its pipeline assets[113] - The company is actively seeking collaborations to support its global development strategy and enhance its product and technology platforms[109] - The company expects potential collaborations to advance its leading asset, osemitamab (TST001), into a global Phase III trial for CLDN18.2 positive gastric cancer, marking a key step in establishing it as a foundational treatment for various solid tumors[111] Risk Management and Compliance - The company faces significant risks including the ability to identify new drug candidates and complete clinical development successfully[168] - The company is committed to fulfilling social responsibilities and promoting sustainable growth while adhering to environmental protection laws and regulations[167] - The company has not been involved in any major disputes with customers or suppliers during the reporting period[178]

Impairment Assessment - The company clarified that the announcement regarding the impairment assessment of goodwill, property, plant and equipment, and intangible assets should be entirely removed, including the title[3] Auditor's Opinion - The auditor confirmed that the opinions stated in the announcement are solely related to going concern issues[3] - The board and auditor believe that the revised announcement is clear and avoids unnecessary confusion or misunderstanding[3] Compliance - The company confirms that the revised announcement fully complies with the listing rules[3]